The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
GI Malignancies Debate 2022 | Surgical advances in in gastric and GEJ cancer
Deepa Magge, MD, FACS, Vanderbilt-Ingram Cancer Center, Nashville, TN, describes the latest surgical developments in gastric and gastro-esophageal junction (GEJ) cancer. Whilst stage T1 gastric cancer is treatable with surgery alone, stage T2 and above gastric cancer required perioperative and adjuvant chemotherapy in addition to surgery. Immunotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) have additionally been promising for patients with microsatellite instable (MSI) and metastatic disease respectively. In the field of GEJ cancer, recent data has suggested the benefit of proximal gastrectomy, due to higher morbidity rates in patients receiving total gastrectomy. This interview took place virtually at the 2022 Great Debates & Updates in Gastrointestinal Malignancies Congress.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
